Emergent Biosolutions Stock Buy Hold or Sell Recommendation
| EBS Stock | USD 5.72 0.01 0.17% |
Considering the 90-day investment horizon and your above-average risk tolerance, our recommendation regarding Emergent Biosolutions is 'Strong Sell'. A buy or sell recommendation is an automated directive regarding whether to purchase or sell Emergent Biosolutions given historical horizon and risk tolerance. When we issue a 'buy' or 'sell' recommendation for Emergent Biosolutions, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Emergent Biosolutions Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Emergent Stock please use our How to Invest in Emergent Biosolutions guide. Note, we conduct extensive research on individual companies such as Emergent and provide practical buy, sell, or hold advice based on investors' constraints. Emergent Biosolutions. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.
Emergent |
Execute Emergent Biosolutions Buy or Sell Advice
The Emergent recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Emergent Biosolutions. Macroaxis does not own or have any residual interests in Emergent Biosolutions or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Emergent Biosolutions' advice using the current market data and latest reported fundamentals.
Time Horizon
3 Months |
Risk Tolerance
I am an educated risk taker |
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Relatively risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Emergent Biosolutions Trading Alerts and Improvement Suggestions
| Emergent Biosolutions generated a negative expected return over the last 90 days | |
| Emergent Biosolutions has high historical volatility and very poor performance | |
| The company reported the last year's revenue of 1.01 B. Reported Net Loss for the year was (190.6 M) with profit before taxes, overhead, and interest of 290.1 M. | |
| About 58.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from globenewswire.com: Emergent BioSolutions Announces Approximately 27 Million in Incremental Sales to Supply International Customers with Five Critical Medical Countermeasure Products |
Emergent Biosolutions Returns Distribution Density
The distribution of Emergent Biosolutions' historical returns is an attempt to chart the uncertainty of Emergent Biosolutions' future price movements. The chart of the probability distribution of Emergent Biosolutions daily returns describes the distribution of returns around its average expected value. We use Emergent Biosolutions price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Emergent Biosolutions returns is essential to provide solid investment advice for Emergent Biosolutions.
| Mean Return | -0.47 |
| Value At Risk | -8.69 |
| Potential Upside | 6.36 |
| Standard Deviation | 4.59 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Emergent Biosolutions historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Emergent Stock Institutional Investors
The Emergent Biosolutions' institutional investors refer to entities that pool money to purchase Emergent Biosolutions' securities or originate loans. These institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds.
| Shares | |||
| Goldman Sachs Group Inc | 2024-12-31 | 969.1 K | |
| Palisade Capital Management Llc | 2024-12-31 | 938.7 K | |
| Susquehanna International Group, Llp | 2024-12-31 | 920.8 K | |
| Connor Clark & Lunn Inv Mgmt Ltd | 2024-12-31 | 902.3 K | |
| Two Sigma Investments Llc | 2024-12-31 | 846.8 K | |
| Qube Research & Technologies | 2024-12-31 | 815.8 K | |
| Assenagon Asset Management Sa | 2024-12-31 | 766.5 K | |
| Trexquant Investment Lp | 2024-12-31 | 701.5 K | |
| Renaissance Technologies Corp | 2024-12-31 | 665.8 K | |
| Vanguard Group Inc | 2024-12-31 | 3.2 M | |
| American Century Companies Inc | 2024-12-31 | 2.1 M |
Emergent Biosolutions Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change To Inventory | (83.2M) | (44M) | (51.9M) | 600K | (24.5M) | (23.3M) | |
| Change In Cash | 453.5M | (45.2M) | 66.3M | (530.9M) | (6.1M) | (5.8M) | |
| Free Cash Flow | 395M | 96.1M | (149.9M) | (257.9M) | 35.8M | 24.0M | |
| Depreciation | 114.5M | 123.8M | 143.3M | 125.1M | 108.8M | 114.2M | |
| Other Non Cash Items | 59M | 33.5M | 19.8M | 485.2M | 39.3M | 36.4M | |
| Capital Expenditures | 141M | 225M | 115.8M | 51.6M | 22.9M | 21.8M | |
| Net Income | 305.1M | 230.9M | (223.8M) | (760.5M) | (190.6M) | (181.1M) | |
| End Period Cash Flow | 621.5M | 576.3M | 642.6M | 111.7M | 105.6M | 100.3M | |
| Change To Netincome | 62.2M | 104.1M | 118.7M | 41.8M | 48.1M | 44.4M | |
| Change Receivables | (8.2M) | 49M | (48.2M) | 114.7M | 131.9M | 138.5M | |
| Net Borrowings | 13.7M | 54.5M | (35.9M) | 564.2M | 648.8M | 681.3M | |
| Investments | (151M) | (225M) | (381.3M) | 178.3M | 125.2M | 131.5M |
Emergent Biosolutions Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Emergent Biosolutions or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Emergent Biosolutions' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Emergent stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.53 | |
β | Beta against Dow Jones | -0.64 | |
σ | Overall volatility | 4.68 | |
Ir | Information ratio | -0.09 |
Emergent Biosolutions Volatility Alert
Emergent Biosolutions exhibits very low volatility with skewness of -0.14 and kurtosis of 1.3. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Emergent Biosolutions' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Emergent Biosolutions' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Emergent Biosolutions Implied Volatility
Emergent Biosolutions' implied volatility exposes the market's sentiment of Emergent Biosolutions stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Emergent Biosolutions' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Emergent Biosolutions stock will not fluctuate a lot when Emergent Biosolutions' options are near their expiration.
Emergent Biosolutions Fundamentals Vs Peers
Comparing Emergent Biosolutions' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Emergent Biosolutions' direct or indirect competition across all of the common fundamentals between Emergent Biosolutions and the related equities. This way, we can detect undervalued stocks with similar characteristics as Emergent Biosolutions or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Emergent Biosolutions' fundamental indicators could also be used in its relative valuation, which is a method of valuing Emergent Biosolutions by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Emergent Biosolutions to competition |
| Fundamentals | Emergent Biosolutions | Peer Average |
| Return On Equity | -0.35 | -0.31 |
| Return On Asset | -0.0422 | -0.14 |
| Profit Margin | (0.19) % | (1.27) % |
| Operating Margin | 0.25 % | (5.51) % |
| Current Valuation | 881.53 M | 16.62 B |
| Shares Outstanding | 54.18 M | 571.82 M |
| Shares Owned By Insiders | 2.15 % | 10.09 % |
| Shares Owned By Institutions | 57.78 % | 39.21 % |
| Number Of Shares Shorted | 6.95 M | 4.71 M |
| Price To Earning | 1.67 X | 28.72 X |
| Price To Book | 0.66 X | 9.51 X |
| Price To Sales | 0.30 X | 11.42 X |
| Revenue | 1.01 B | 9.43 B |
| Gross Profit | 290.1 M | 27.38 B |
| EBITDA | 36.9 M | 3.9 B |
| Net Income | (190.6 M) | 570.98 M |
| Cash And Equivalents | 642.6 M | 2.7 B |
| Cash Per Share | 7.28 X | 5.01 X |
| Total Debt | 663.7 M | 5.32 B |
| Debt To Equity | 0.56 % | 48.70 % |
| Current Ratio | 3.92 X | 2.16 X |
| Book Value Per Share | 9.40 X | 1.93 K |
| Cash Flow From Operations | 58.7 M | 971.22 M |
| Short Ratio | 5.21 X | 4.00 X |
| Earnings Per Share | (11.22) X | 3.12 X |
| Price To Earnings To Growth | 1.55 X | 4.89 X |
| Target Price | 12.0 | |
| Number Of Employees | 900 | 18.84 K |
| Beta | 1.57 | -0.15 |
| Market Capitalization | 540.22 M | 19.03 B |
| Total Asset | 1.39 B | 29.47 B |
| Retained Earnings | (212.4 M) | 9.33 B |
| Working Capital | 436.3 M | 1.48 B |
Note: Disposition of 683 shares by Richard Lindahl of Emergent Biosolutions at 7.48 subject to Rule 16b-3 [view details]
Emergent Biosolutions Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Emergent . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Emergent Biosolutions Buy or Sell Advice
When is the right time to buy or sell Emergent Biosolutions? Buying financial instruments such as Emergent Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Emergent Biosolutions in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Impulse Thematic Idea Now
Impulse
Large corporations operating in retail, broadcasting, energy, airlines and telecom sectors. The Impulse theme has 39 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Impulse Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Emergent Stock Analysis
When running Emergent Biosolutions' price analysis, check to measure Emergent Biosolutions' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Emergent Biosolutions is operating at the current time. Most of Emergent Biosolutions' value examination focuses on studying past and present price action to predict the probability of Emergent Biosolutions' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Emergent Biosolutions' price. Additionally, you may evaluate how the addition of Emergent Biosolutions to your portfolios can decrease your overall portfolio volatility.